Cargando…

Let-7 miRNA-binding site polymorphism in the KRAS 3(′)UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab

BACKGROUND: Recent studies have reported associations between a variant allele in a let-7 microRNA complementary site (LCS6) within the 3(′)untranslated region (3(′)UTR) of KRAS (rs61764370) and clinical outcome in metastatic colorectal cancer (mCRC) patients receiving cetuximab. The variant allele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kjersem, Janne B, Ikdahl, Tone, Guren, Tormod, Skovlund, Eva, Sorbye, Halfdan, Hamfjord, Julian, Pfeiffer, Per, Glimelius, Bengt, Kersten, Christian, Solvang, Hiroko, Tveit, Kjell M, Kure, Elin H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526507/ https://www.ncbi.nlm.nih.gov/pubmed/23167843 http://dx.doi.org/10.1186/1471-2407-12-534

Ejemplares similares

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
por: Kjersem, Janne B, et al.
Publicado: (2014)

Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
por: Tarpgaard, Line S., et al.
Publicado: (2014)

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
por: Thomsen, Maria, et al.
Publicado: (2016)

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
por: Guren, Tormod Kyrre, et al.
Publicado: (2017)

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2016)

Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
por: Thomsen, Maria, et al.
Publicado: (2018)

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer
por: Tarpgaard, Line S., et al.
Publicado: (2016)

Differential Expression of miRNAs in Colorectal Cancer: Comparison of Paired Tumor Tissue and Adjacent Normal Mucosa Using High-Throughput Sequencing
por: Hamfjord, Julian, et al.
Publicado: (2012)

Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
por: Hamfjord, Julian, et al.
Publicado: (2022)

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer
por: Siesing, Christina, et al.
Publicado: (2017)

Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2017)

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
por: Winther, Stine Braendegaard, et al.
Publicado: (2017)

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
por: Garufi, C, et al.
Publicado: (2010)

The level of claudin-7 is reduced as an early event in colorectal carcinogenesis
por: Bornholdt, Jette, et al.
Publicado: (2011)

Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer
por: Wei, Li, et al.
Publicado: (2020)

Health-Related Quality of Life in Colorectal Cancer Patients Treated With Liver Transplantation Compared to Chemotherapy
por: Smedman, Tor Magnus, et al.
Publicado: (2022)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
por: Narvi, Elli, et al.
Publicado: (2018)

Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma
por: Lorentzen, Anders, et al.
Publicado: (2007)

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
por: Glimelius, B, et al.
Publicado: (2011)

Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer
por: Santoro, Valeria, et al.
Publicado: (2015)

The Effect of Compound Sophora on Fluorouracil and Oxaliplatin Resistance in Colorectal Cancer Cells
por: Yin, WeiHua, et al.
Publicado: (2019)

A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
por: Carlsson, G., et al.
Publicado: (2022)

Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
por: Chau, I, et al.
Publicado: (2001)

A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer
por: Cheeseman, S L, et al.
Publicado: (2002)

Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
por: Lee, J. H., et al.
Publicado: (2001)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
por: Bai, Liangliang, et al.
Publicado: (2019)

Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)
por: Kotake, Masanori, et al.
Publicado: (2017)

Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2022)

Collagen mRNA levels changes during colorectal cancer carcinogenesis
por: Skovbjerg, Hanne, et al.
Publicado: (2009)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
por: Hashimoto, Akari, et al.
Publicado: (2014)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205
por: Flis, Sylwia, et al.
Publicado: (2009)

Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells
por: Frerker, Bernd, et al.
Publicado: (2023)

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
por: Aasebø, Kristine, et al.
Publicado: (2020)

HLA-G 3′UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer
por: Garziera, Marica, et al.
Publicado: (2017)

Consequences of a high incidence of microsatellite instability and BRAF‐mutated tumors: A population‐based cohort of metastatic colorectal cancer patients
por: Aasebø, Kristine Ø., et al.
Publicado: (2019)

Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas
por: Skjelbred, Camilla F, et al.
Publicado: (2007)

The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study
por: Andersen, Vibeke, et al.
Publicado: (2009)

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
por: Buchler, Tomas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9d389bqcp3946gj1tuh1s9hjm1